PHR241220P35000
- 0.00
- 0.000.00%
Phreesia Newsroom
D.A. Davidson Maintains Phreesia(PHR.US) With Buy Rating, Announces Target Price $32
Phreesia's Strong Growth Prospects and Strategic Financial Position Justify Buy Rating
Phreesia Named to The Software Report's "Top 100 Software Companies" for the Third Consecutive Year
Phreesia (NYSE:PHR Investor Three-year Losses Grow to 71% as the Stock Sheds US$165m This Past Week
Phreesia Down Over 16%, on Pace for Largest Percent Decrease Since September 2023 -- Data Talk
Phreesia (PHR) Moves 13.9% Higher: Will This Strength Last?
CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
Phreesia Sets Release Date for Fiscal Third Quarter 2025 Results
Phreesia Achieves Oracle Validated Integration With Oracle Health EHR Expertise for Delivering Proven, Repeatable Integration
Phreesia, Inc.'s (NYSE:PHR) Price In Tune With Revenues
Down -10.25% in 4 Weeks, Here's Why Phreesia (PHR) Looks Ripe for a Turnaround
Phreesia Joins the Network Advertising Initiative as a Member, Demonstrating Ongoing Commitment to Industry-Leading Privacy Practices
Phreesia and Ad Council Partnership Yields High Patient Engagement in 3 Mental Health Awareness Campaigns
Phreesia Rises After New Contract
Express News | Phreesia: Contract With CMS Innovation Center (Cmmi) for Use of Patient Activation Measure® (PAM) Has Been Renewed Through 2029
Phreesia Secures New Contract With CMS as Report Shows Gains in Patient Activation in First Year of Kidney Care Choices (KCC) Model
RBC Capital Maintains Phreesia(PHR.US) With Hold Rating, Maintains Target Price $23
Is Phreesia (NYSE:PHR) A Risky Investment?
巴克莱银行维持Phreesia(PHR.US)买入评级，维持目标价29美元
Barclays analyst Stephanie Davis maintains $Phreesia(PHR.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 43.4% and a total
Phreesia (PHR) Gets a Buy From Barclays